1. Home
  2. MLAC vs TRDA Comparison

MLAC vs TRDA Comparison

Compare MLAC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLAC
  • TRDA
  • Stock Information
  • Founded
  • MLAC 2024
  • TRDA 2016
  • Country
  • MLAC United States
  • TRDA United States
  • Employees
  • MLAC N/A
  • TRDA N/A
  • Industry
  • MLAC
  • TRDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MLAC
  • TRDA Health Care
  • Exchange
  • MLAC NYSE
  • TRDA Nasdaq
  • Market Cap
  • MLAC 316.6M
  • TRDA 292.2M
  • IPO Year
  • MLAC 2024
  • TRDA 2021
  • Fundamental
  • Price
  • MLAC $10.23
  • TRDA $8.32
  • Analyst Decision
  • MLAC
  • TRDA Strong Buy
  • Analyst Count
  • MLAC 0
  • TRDA 3
  • Target Price
  • MLAC N/A
  • TRDA $25.67
  • AVG Volume (30 Days)
  • MLAC 32.5K
  • TRDA 141.6K
  • Earning Date
  • MLAC 01-01-0001
  • TRDA 05-08-2025
  • Dividend Yield
  • MLAC N/A
  • TRDA N/A
  • EPS Growth
  • MLAC N/A
  • TRDA N/A
  • EPS
  • MLAC N/A
  • TRDA 0.61
  • Revenue
  • MLAC N/A
  • TRDA $172,220,000.00
  • Revenue This Year
  • MLAC N/A
  • TRDA N/A
  • Revenue Next Year
  • MLAC N/A
  • TRDA N/A
  • P/E Ratio
  • MLAC $416.77
  • TRDA $13.80
  • Revenue Growth
  • MLAC N/A
  • TRDA 5.74
  • 52 Week Low
  • MLAC $9.94
  • TRDA $7.10
  • 52 Week High
  • MLAC $10.23
  • TRDA $21.79
  • Technical
  • Relative Strength Index (RSI)
  • MLAC N/A
  • TRDA 51.75
  • Support Level
  • MLAC N/A
  • TRDA $7.70
  • Resistance Level
  • MLAC N/A
  • TRDA $8.50
  • Average True Range (ATR)
  • MLAC 0.00
  • TRDA 0.39
  • MACD
  • MLAC 0.00
  • TRDA 0.08
  • Stochastic Oscillator
  • MLAC 0.00
  • TRDA 77.67

About MLAC MOUNTAIN LAKE ACQUISITION CORP

Mountain Lake Acquisition Corp is a blank check company.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Share on Social Networks: